YONDELIS® (trabectedin) now PBS listed for Australian patients Listing described as “wonderful news” for patients living with rare lipo and leiomyo sarcomas YONDELISÒ (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine1 SINGAPORE, July 31,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.